Biosimilars or follow-on-biologics are the “copied” version of reference biologics, which are protected by intellectual rights that will expire soon. Patent expiration is the major driving factor of the biosimilars market.

1. Why Biosimilars superior to Biologics?

2. 105 Pages
Report
Published Date: 18 March 2014Published Date : 07 April 2014
95 Pages
Report
Published Date: 08 April 2014
108 Pages
Report
86 Pages
Report
Published Date : 15 April 2014
112 Pages
Report
Published Date : 21 April 2014
145 Pages
Report
Published Date : 25 June 2014
114 Pages
Report
Published Date : 30 June 2014Published Date: 1 July 2014
140 Pages
Report
184 Pages
Report

3. Table of Content
1. Introduction
2. Executive Summary
3. Global 3D Technology Market Overview
4. Global 3D Technology Market by Products
5. Global 3D Technology Market by Applications
6. Global 3D Technology Market by Geography
7. Company Profiles
Introduction
Scope of the Report Key Benefits
Key Audiences

4. 1. INTRODUCTION
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
4. GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY TECHNOLOGY
5. GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY PRODUCT TYPE
6. GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY APPLICATIONS
7. GLOBAL BIOSIMILARS / FOLLOW-ON-BIOLOGICS MARKET BY SERVICES
8. GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET BY GEOGRAPHIES
9. KEY PRODUCTS AND RECENT ACTIVITIES BY GEOGRAPHY
10 . COMPANY PROFILES
Table of Contents

5. Description
Biosimilars or follow-on-biologics are the “copied” version of reference biologics,
which are protected by intellectual rights that will expire soon. Patent expiration is
the major driving factor of the biosimilars market. Most of the blockbuster patents
will expire by the end of 2014, which would provide a competitive edge to local
pharmaceutical manufacturers over the global players.
For instance, patents for insulin glargine will expire by the end of this year, which
would give an opportunity for the growth of insulin biosimilars market. Global
biosimilars/follow-on-biologics market accounted for $1,358 million in 2013 and it is
anticipated to generate $35,032 million by 2020, growing at a CAGR of 60.8% from
2014 to 2020. Regulations for biosimilars plays a vital role in maintaining the
viability and balance between original and biosimilar products.
Various regulatory authorities, namely EMA and the U.S. FDA are actively regulating
the biosimilars market. Regulations in the European union are considered
benchmark around the world, as the guidelines proposed are most stringent for
validation and commercialization of biosimilars. High profitability is the attractive
aspect that is enticing companies to invest in the biosimilars industry.

6. The study is segmented in a strategic divisions to gain deeper insights into the market dynamics
and understand the competitive environment of the overall market
Financial market forecast is provided for the next eight years by considering 2013 as the base
year
Comprehensive and quantitative data about changing market trends, intensifying competition and
opportunities in biosimilars market are provided to make better business decisions
Porter’s Five Forces model and SWOT analysis of the overall market is provided to help
stakeholders gain strategic insights of the market
Deep dive analysis of key market players and strategies adopted by them are expounded to
provide valuable information on the top contenders in the market
Identification of key investment pockets for the biosimilars market is strategically dealt to assist
the stakeholders
KEY BENEFITS

7. Global Biosimilars Market Overview
Value chain
analysis
Global
Biosimilars
Market
OverviewPorters five
force
analysis
Market
Definition and
Scope
Diverse
approach of
global
regulators
towards
biosimilars
Key
Findings
Safety issues
of biosimilar
drugs
Emerging
economies a
hotspot for
biosimilars
market
Regulation &
Reimbursement
scenario

8. Your feedback is important to us
What would you like to know more about this Study ?
 Global Industry Analysis
 Market Size
 Market Share
 Market Trends
Opportunities and Forecast
Please inform us on : http://www.alliedmarketresearch.com/contact-us
Market Dynamics
Key Market
Drivers
Market
Restraints
High cost of
Production
Market Dynamics
Growing
pressure to
reduce
healthcare
expenditure
Economic and
scientific
obstacles
Medical Efficacy and
Patient Safety
Various
blockbusters
going off
patent
High
prevalence of
chronic
diseases
among
population
Lower cost
biosimilars
drugs than
original
biologics
High initial
investment in
research and
development

9. GLOBAL
BIOSIMILARS/FOL
LOW-ON-
BIOLOGICS
MARKET BY
APPLICATIONS
Blood disorders
Oncology diseases
Chronic and
autoimmune
diseases
Growth hormone
deficiency
Others
GLOBAL BIOSIMILARS/FOLLOW-ON-BIOLOGICS MARKET By
APPLICATIONS

10. GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET BY
TECHNOLOGIES
Market
By
Technologies
Bioassay
Western Blotting
MASS SPECTROMETRY
Electrophoresis
Nuclear magnetic resonance
(NMR) technology
Chromatography
Recombinant DNA
Technology
Monoclonal Antibodies
(MAb) Technology

11. GLOBAL BIOSIMILARS/FOLLO-ON-BIOLOGICS MARKET By ,
GEOGRAPHY

12. Top Market Players of Biosimilars/Follo-On-Biologics Market
 Novartis (Sandoz)
 Synthon Pharmaceuticals, Inc.
 Teva Pharmaceutical Industries Ltd.
 LG Life Sciences
 Celltrion
 Biocon
 Hospira
 Merck Serono (Merck Group)
 Biogen idec Inc.
 Genentech (Roche Group)

13. Your feedback is important to us
What would you like to know more about this Study ?
 Global Industry Analysis
 Market Size
 Market Share
 Market Trends
Opportunities and Forecast
Please inform us on : http://www.alliedmarketresearch.com/contact-us

14. To View the Complete Report
Visit -
http://www.alliedmarketresearch.com/
biosimilars-market